Cargando…

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2021
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080893/ https://www.ncbi.nlm.nih.gov/pubmed/33999039 http://dx.doi.org/10.3233/BLC-219500

Ejemplares similares

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer(1)
Publicado: (2020)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer(1)
por: Tu, Megan M., et al.
Publicado: (2019)

Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies
por: Ilcus, Cristina, et al.
Publicado: (2017)

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
por: Ma, Weijie, et al.
Publicado: (2016)

β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer
por: Wang, Mengjie, et al.
Publicado: (2022)

Drug response to PD-1/PD-L1 blockade: based on biomarkers
por: Chen, Qi, et al.
Publicado: (2018)

Immunotherapy of alveolar echinococcosis via PD‐1/PD‐L1 immune checkpoint blockade in mice
por: Wang, Junhua, et al.
Publicado: (2018)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
por: Wu, Bogang, et al.
Publicado: (2018)

A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints
por: Li, Yongshu, et al.
Publicado: (2016)

Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
por: Grecea, Miruna, et al.
Publicado: (2021)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint
por: Koopmans, Iris, et al.
Publicado: (2018)

Genetic biomarkers for PD-1/PD-L1 blockade therapy
por: Kataoka, Keisuke, et al.
Publicado: (2016)

Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes
por: Zheng, Dan, et al.
Publicado: (2022)

Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade
por: Klepsch, Victoria, et al.
Publicado: (2018)

Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment
por: Oh, So Yeon, et al.
Publicado: (2021)

PD-1 checkpoint blockade in advanced melanoma patients: NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates
por: Pico de Coaña, Yago, et al.
Publicado: (2020)

Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer
por: Kok, Victor C.
Publicado: (2020)

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
por: Lipson, Evan J., et al.
Publicado: (2017)

Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle
por: Zhuang, Yuan, et al.
Publicado: (2020)

PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer
por: Bocanegra, Ana, et al.
Publicado: (2019)

Further investigation of blockade effects and binding affinities of selected natural compounds to immune checkpoint PD-1/PD-L1
por: Li, Huifang, et al.
Publicado: (2022)

Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade
por: Zhang, Fei, et al.
Publicado: (2017)

DNA Methylation Biomarkers Predict Objective Responses to PD-1/PD-L1 Inhibition Blockade
por: Xue, Gang, et al.
Publicado: (2019)

Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer
por: Zhang, Yuedi, et al.
Publicado: (2022)

PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade
por: Peng, Qi, et al.
Publicado: (2020)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Biomarkers of response to PD-1 pathway blockade
por: Li, Hanxiao, et al.
Publicado: (2022)

Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer
por: Sharma, Meenal, et al.
Publicado: (2019)

Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer
por: Luo, Fan, et al.
Publicado: (2019)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
por: Ren, Daixi, et al.
Publicado: (2020)

Relapsing Polychondritis following PD-1 Blockade by an Immune Checkpoint Inhibitor
por: Mutoh, Tomoyuki, et al.
Publicado: (2023)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
por: Hashimoto, Kazuhiko, et al.
Publicado: (2020)

Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy
por: Escors, David, et al.
Publicado: (2022)

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
por: Lee, Hyun Tae, et al.
Publicado: (2017)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

A meta-analysis of the efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors as treatments for metastatic bladder cancer
por: Fan, Zhongyuan, et al.
Publicado: (2019)

Immune Checkpoint Blockade Anti–PD-L1 as a Trigger for Autoimmune Polyendocrine Syndrome
por: Lanzolla, Giulia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kcgp3ohdkotntmo7abcjljvrd1